Revolution Medicines to Participate in Upcoming April 2024 Investor Conferences

2024-04-04

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum. Details of the company’s participation are as follows: 23rd Annual Needham Healthcare Conference Conference Dates: April 8-11, 2024 Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024 Location: Virtual; webcast available Stifel Targeted Oncology Forum Conference Dates: April 16-17, 2024 Fireside Chat Time/Date: 3:30 – 3:55 p.m. ET on Tuesday, April 16, 2024 Location: Virtual; webcast available To access the live webcasts of the Needham and Stifel fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at . Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference. About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). Media & Investor Contact Erin Graves 650-779-0136 egraves@revmed.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构